First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer

First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer
A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of the chemotherapy docetaxel. Doctors administer it with ritonavir, which increases the amount of docetaxel absorbed by the body. Being an oral formulation, ModraDoc006/r allows patients to receive chemotherapy at home, and scientists believe it poses a lower risk for toxicities (namely low counts of immune cells and damage to the nerves), and an increased effectiveness. “Intravenously administered chemotherapy is widely used, but nevertheless always involves a significant time investment for patients in regard to travel to and from the clinic and receiving the treatment itself, as well as the considerable burden of dealing with its side effects,” Ulka Vaishampayan, MD, said in a press release. Vaishampayan is principal investigator of the trial and a professor of oncology at the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan. “To that end, ModraDoc006/r has the potential to become an exciting new oral option for prostate cancer which retains or improves on the therapeutic characteristics of docetaxel and easily incorporates chemotherapy
Subscribe or to access all post and page content.